Skip to main content
Top
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases

Authors: Zhihong Chi, Siming Li, Xinan Sheng, Lu Si, Chuanliang Cui, Mei Han, Jun Guo

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

Malignant melanoma is a rare disease in Asia, and knowledge on its characteristics and clinical outcome in Asian patients is limited. The purpose of this observational study was to determine the clinical presentation and outcome of patients with melanoma in China.

Methods

A database was prospectively established for the purpose of this analysis. The elements of the database included basic demographic data of patients and prognosticators previously reported in literature, as well as follow-up data including clinical outcome after treatment. Medical record of all patients with pathologically diagnosed malignant melanoma consulted in our center since 2006 were retrieved and reviewed. No patient was excluded in this study. Statistical analyses including survival and multivariate analyses of factors associated with survival were respectively performed by Kaplan-Meier method and Cox proportional hazard model.

Results

A total of 522 consecutive and nonselected cases were evaluated. There were 218 cases (41.8%) of acral lentiginous melanoma (ALM), 118 (22.6%) of mucosal melanoma (MCM), 103 (19.7%) of nodular melanoma (NM), 33 (6.3%) of superficial spreading melanoma (SSM), and others were Lentigo maligna melanoma or unclassifiable disease. The proportion of patients with clinical stage I, II, III, and IV diseases were 6.1%, 55.9%, 25.1%, and 12.8%, respectively. Among the 357 cases of cutaneous melanoma, 234 patients (65.5%) had ulceration.
The 5-year overall survival rate of all 522 patients was 41.6%, and the median survival time was 3.92 years (95% CI, 3.282 to 4.558). Five-year survival rates of patients with stage I, II, III, and IV diseases were 94.1%, 44.0%, 38.4% and 4.6% respectively (P < 0.001). Multivariate analysis revealed that clinical stage and the ulceration were two significant prognosticators for OS. In addition, extent of surgery and use of adjuvant therapy were significant prognosticators for DFS in patients with non-metastatic disease after definitive treatment. Pathological subtype was not a significant prognostic factor to predict wither OS or DFS.

Conclusions

Prognoses of patients with malignant melanoma diagnosed in China were suboptimal, and most patients were diagnosed with locally advanced disease (i.e., stage II or above). ALM and MCM are the two most commonly diagnosed pathological subtypes. Clinical staging and presence of ulceration was significantly associated with clinical outcome in terms of OS, while treatment strategy including extent of surgery and use of adjuvant therapy were significant predictors of DFS.
Appendix
Available only for authorised users
Literature
1.
go back to reference Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P: Cancer Incidence in Five Continents. 2007, IARC Scientific Publications No. 160, Lyon: IARC, IX: Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P: Cancer Incidence in Five Continents. 2007, IARC Scientific Publications No. 160, Lyon: IARC, IX:
2.
go back to reference Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 2009, 59 (4): 225-249. 10.3322/caac.20006.CrossRefPubMed Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 2009, 59 (4): 225-249. 10.3322/caac.20006.CrossRefPubMed
3.
go back to reference Cormier JN, Xing Y, Ding M, Lee JE, Mansfield PF, Gershenwald JE, Ross MI, Du XL: Ethnic differences among patients with cutaneous melanoma. Arch Internal Medicine. 2006, 166: 1907-1914. 10.1001/archinte.166.17.1907.CrossRef Cormier JN, Xing Y, Ding M, Lee JE, Mansfield PF, Gershenwald JE, Ross MI, Du XL: Ethnic differences among patients with cutaneous melanoma. Arch Internal Medicine. 2006, 166: 1907-1914. 10.1001/archinte.166.17.1907.CrossRef
4.
go back to reference Halder RM, Bridgeman-Shah S: Skin cancer in African Americans. Cancer. 1995, 75 (2 Suppl): 667-673. 10.1002/1097-0142(19950115)75:2+<667::AID-CNCR2820751409>3.0.CO;2-I.CrossRefPubMed Halder RM, Bridgeman-Shah S: Skin cancer in African Americans. Cancer. 1995, 75 (2 Suppl): 667-673. 10.1002/1097-0142(19950115)75:2+<667::AID-CNCR2820751409>3.0.CO;2-I.CrossRefPubMed
5.
go back to reference Bellows CF, Belafsky P, Fortgang IS, Beech DJ: Melanoma in African-Americans: trends in biological behavior and clinical characteristics over two decades. J Surg Oncol. 2001, 78 (1): 10-6. 10.1002/jso.1116.CrossRefPubMed Bellows CF, Belafsky P, Fortgang IS, Beech DJ: Melanoma in African-Americans: trends in biological behavior and clinical characteristics over two decades. J Surg Oncol. 2001, 78 (1): 10-6. 10.1002/jso.1116.CrossRefPubMed
6.
go back to reference Shoo BA, Kashani-Sabet M: Melanoma arising in African-, Asian-, Latino- and Native-American populations. Semin Cutan Med Surg. 2009, 28 (2): 96-102. 10.1016/j.sder.2009.04.005.CrossRefPubMed Shoo BA, Kashani-Sabet M: Melanoma arising in African-, Asian-, Latino- and Native-American populations. Semin Cutan Med Surg. 2009, 28 (2): 96-102. 10.1016/j.sder.2009.04.005.CrossRefPubMed
7.
go back to reference Ishihara K, Saida T, Yamamoto A: Updated statistical data for malignant melanoma in Japan. Int J Clin Oncol. 2001, 6 (3): 109-116. 10.1007/PL00012091.CrossRefPubMed Ishihara K, Saida T, Yamamoto A: Updated statistical data for malignant melanoma in Japan. Int J Clin Oncol. 2001, 6 (3): 109-116. 10.1007/PL00012091.CrossRefPubMed
8.
go back to reference Ishihara K, Saida T, Otsuka F, Yamazaki N: Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update. Int J Clin Oncol. 2008, 13 (1): 33-41. 10.1007/s10147-007-0751-1.CrossRefPubMed Ishihara K, Saida T, Otsuka F, Yamazaki N: Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update. Int J Clin Oncol. 2008, 13 (1): 33-41. 10.1007/s10147-007-0751-1.CrossRefPubMed
9.
go back to reference Chang JW, Yeh KY, Wang CH, Yang TS, Chiang HF, Wei FC, Kuo TT, Yang CH: Malignant melanoma in Taiwan: a prognostic study of 181 cases. Melanoma Res. 2004, 14 (6): 537-541. 10.1097/00008390-200412000-00016.CrossRefPubMed Chang JW, Yeh KY, Wang CH, Yang TS, Chiang HF, Wei FC, Kuo TT, Yang CH: Malignant melanoma in Taiwan: a prognostic study of 181 cases. Melanoma Res. 2004, 14 (6): 537-541. 10.1097/00008390-200412000-00016.CrossRefPubMed
10.
go back to reference Balch CM, buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001, 19 (16): 3635-3648.PubMed Balch CM, buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001, 19 (16): 3635-3648.PubMed
11.
go back to reference Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958, 53: 457-481. 10.2307/2281868.CrossRef Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958, 53: 457-481. 10.2307/2281868.CrossRef
12.
go back to reference Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK: SEER Cancer Statistics Review, 1975-2007. 2010, National Cancer Institute. Bethesda, MD, Accessed on November 25, 2010, [http://seer.cancer.gov/csr/1975_2007/] Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK: SEER Cancer Statistics Review, 1975-2007. 2010, National Cancer Institute. Bethesda, MD, Accessed on November 25, 2010, [http://​seer.​cancer.​gov/​csr/​1975_​2007/​]
13.
go back to reference Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996, 14 (1): 7-17.PubMed Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996, 14 (1): 7-17.PubMed
14.
go back to reference MacKie RM, Bray C, Vestey J, Doherty V, Evans A, Thomson D, Nicolson M: Melanoma incidence and mortality in Scotland 1979-2003. Br J Cancer. 2007, 96 (11): 1772-1777. 10.1038/sj.bjc.6603801.CrossRefPubMedPubMedCentral MacKie RM, Bray C, Vestey J, Doherty V, Evans A, Thomson D, Nicolson M: Melanoma incidence and mortality in Scotland 1979-2003. Br J Cancer. 2007, 96 (11): 1772-1777. 10.1038/sj.bjc.6603801.CrossRefPubMedPubMedCentral
15.
go back to reference Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, Bardia A, Vachon CM, Schild SE, McWilliams RR, Hand JL, Laman SD, Kottschade LA, Maples WJ, Pittelkow MR, Pulido JS, Cameron JD, Creagan ET: Malignant Melanoma in the 21st Century, Part 2: Staging, Prognosis, and Treatment. Mayo Clin Proc. 2007, 82 (4): 490-513. 10.4065/82.4.490.CrossRefPubMed Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, Bardia A, Vachon CM, Schild SE, McWilliams RR, Hand JL, Laman SD, Kottschade LA, Maples WJ, Pittelkow MR, Pulido JS, Cameron JD, Creagan ET: Malignant Melanoma in the 21st Century, Part 2: Staging, Prognosis, and Treatment. Mayo Clin Proc. 2007, 82 (4): 490-513. 10.4065/82.4.490.CrossRefPubMed
16.
go back to reference Ishihara K, Saida T, Yamamoto A: Nationwide survey of malignant melanoma (1992-1998). Skin Cancer (Japan). 2000, 15 (1): 7-14.CrossRef Ishihara K, Saida T, Yamamoto A: Nationwide survey of malignant melanoma (1992-1998). Skin Cancer (Japan). 2000, 15 (1): 7-14.CrossRef
17.
go back to reference Gimotty PA, Botbyl J, Soong SH, Guerry D: A population-based validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol. 2005, 23 (31): 8065-8075. 10.1200/JCO.2005.02.4976.CrossRefPubMed Gimotty PA, Botbyl J, Soong SH, Guerry D: A population-based validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol. 2005, 23 (31): 8065-8075. 10.1200/JCO.2005.02.4976.CrossRefPubMed
18.
go back to reference Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH, Morabito A: Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001, 19 (16): 3622-3634.PubMed Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH, Morabito A: Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001, 19 (16): 3622-3634.PubMed
19.
go back to reference Bradford PT, Goldstein AM, McMaster ML, Tucker MA: Acral lentiginous melanoma: Incidence and survival patterns in the United States, 1986-2005. Arch Dermatol. 2009, 145 (4): 427-434. 10.1001/archdermatol.2008.609.CrossRefPubMedPubMedCentral Bradford PT, Goldstein AM, McMaster ML, Tucker MA: Acral lentiginous melanoma: Incidence and survival patterns in the United States, 1986-2005. Arch Dermatol. 2009, 145 (4): 427-434. 10.1001/archdermatol.2008.609.CrossRefPubMedPubMedCentral
20.
go back to reference Reed RJ: New Concepts in Surgical Pathology of the Skin. 1976, New York: John Wiley & Sons, 89-90. Reed RJ: New Concepts in Surgical Pathology of the Skin. 1976, New York: John Wiley & Sons, 89-90.
21.
go back to reference Krementz ET, Feed RJ, Coleman WP, Sutherland CM, Carter RD, Campbell M: Acral lentiginous melanoma. A clinicopathologic entity. Ann Surg. 1982, 195 (5): 632-645. 10.1097/00000658-198205000-00013.CrossRefPubMedPubMedCentral Krementz ET, Feed RJ, Coleman WP, Sutherland CM, Carter RD, Campbell M: Acral lentiginous melanoma. A clinicopathologic entity. Ann Surg. 1982, 195 (5): 632-645. 10.1097/00000658-198205000-00013.CrossRefPubMedPubMedCentral
22.
go back to reference Ishihara K, Saida T, Otsuka F, Yamazaki N: Staistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update. Int J Clin Oncol. 2008, 13 (1): 33-41. 10.1007/s10147-007-0751-1.CrossRefPubMed Ishihara K, Saida T, Otsuka F, Yamazaki N: Staistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update. Int J Clin Oncol. 2008, 13 (1): 33-41. 10.1007/s10147-007-0751-1.CrossRefPubMed
23.
go back to reference Mendenhall WM, Amdur RJ, Hinerman RW, Werning JW, Villaret DB, Mendenhall NP: Head and neck mucosal melanoma. Am J Clin Oncol. 2005, 28 (6): 626-630. 10.1097/01.coc.0000170805.14058.d3.CrossRefPubMed Mendenhall WM, Amdur RJ, Hinerman RW, Werning JW, Villaret DB, Mendenhall NP: Head and neck mucosal melanoma. Am J Clin Oncol. 2005, 28 (6): 626-630. 10.1097/01.coc.0000170805.14058.d3.CrossRefPubMed
24.
go back to reference Henderson MA, Burmeister B, Thompson JF, Di lulio J, Fisher R, Hong A, Scolyer R, Shannon K, Hoesktra H, Ainslie J: Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01). J Clin Oncol. 2009, 27 (18s): suppl; abstr LBA9084 Henderson MA, Burmeister B, Thompson JF, Di lulio J, Fisher R, Hong A, Scolyer R, Shannon K, Hoesktra H, Ainslie J: Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01). J Clin Oncol. 2009, 27 (18s): suppl; abstr LBA9084
25.
go back to reference Verma S, Quirt I, McCready D, Bak K, Charette M, Iscoe N: Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer. 2006, 106 (7): 1431-42. 10.1002/cncr.21760.CrossRefPubMed Verma S, Quirt I, McCready D, Bak K, Charette M, Iscoe N: Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer. 2006, 106 (7): 1431-42. 10.1002/cncr.21760.CrossRefPubMed
26.
go back to reference Mocellin S, Pasquali S, Rossi CR, Nitti D: Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2010, 102 (7): 493-501. 10.1093/jnci/djq009.CrossRefPubMed Mocellin S, Pasquali S, Rossi CR, Nitti D: Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2010, 102 (7): 493-501. 10.1093/jnci/djq009.CrossRefPubMed
27.
go back to reference Sasse AD, Sasse EC, Clark LG, Ulloa L, Clark OA: Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev. 2007, 1: CD005413-PubMed Sasse AD, Sasse EC, Clark LG, Ulloa L, Clark OA: Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev. 2007, 1: CD005413-PubMed
28.
go back to reference Hainsworth JD, Infante JR, Spigel DR, Peyton JD, Thompson DS, Lane CM, Clark BL, Rubin MS, Trent DF, Burris HA: Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer. 2010, 116 (17): 4122-4129. 10.1002/cncr.25320.CrossRefPubMed Hainsworth JD, Infante JR, Spigel DR, Peyton JD, Thompson DS, Lane CM, Clark BL, Rubin MS, Trent DF, Burris HA: Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer. 2010, 116 (17): 4122-4129. 10.1002/cncr.25320.CrossRefPubMed
29.
go back to reference Vihinen PP, Hernberg M, Vuoristo MS, Tyynelä K, Laukka M, Lundin J, Ivaska J, Pyrhönen S: A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma. Melanoma Res. 2010, 20 (4): 318-325. 10.1097/CMR.0b013e3283390365.CrossRefPubMed Vihinen PP, Hernberg M, Vuoristo MS, Tyynelä K, Laukka M, Lundin J, Ivaska J, Pyrhönen S: A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma. Melanoma Res. 2010, 20 (4): 318-325. 10.1097/CMR.0b013e3283390365.CrossRefPubMed
30.
go back to reference Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J, Peschel C, Schadendorf D, Garbe C, O'Day S, Daud A, White JM, Xia C, Patel K, Kirkwood JM, Keilholz U: Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009, 27 (17): 2823-2830. 10.1200/JCO.2007.15.7636.CrossRefPubMed Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J, Peschel C, Schadendorf D, Garbe C, O'Day S, Daud A, White JM, Xia C, Patel K, Kirkwood JM, Keilholz U: Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009, 27 (17): 2823-2830. 10.1200/JCO.2007.15.7636.CrossRefPubMed
31.
go back to reference O'Day S, Hodi FS, McDermott DF, Weber RW, Sosman JA, Haanen JB, Zhu X, Yellin MJ, Hoos A, Urba WJ: A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma. J Clin Oncol. 2010, 28 (18s): suppl; abstr 4 O'Day S, Hodi FS, McDermott DF, Weber RW, Sosman JA, Haanen JB, Zhu X, Yellin MJ, Hoos A, Urba WJ: A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma. J Clin Oncol. 2010, 28 (18s): suppl; abstr 4
Metadata
Title
Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases
Authors
Zhihong Chi
Siming Li
Xinan Sheng
Lu Si
Chuanliang Cui
Mei Han
Jun Guo
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-85

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine